[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:systemic-scleroderma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":282,"states":290},"Systemic Scleroderma",44,37,[8,16,23,29,35,41,48,54,61,68,74,80,87,93,99,105,111,117,123,129,135,141,147,153,159,165,171,177,184,190,196,202,208,214,220,226,232,238,244,250,256,262,269,275],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05029336","Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases",[12],"Phase 2","RECRUITING","2026-08-26T02:19:10.436356Z","2026-05-05T02:43:29.737040Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06328777","RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:26.932189Z","2026-05-05T02:43:29.339342Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06195072","Platform Clinical Study for Conquering Scleroderma",[12],"2026-08-26T02:17:53.433613Z","2026-05-05T02:43:29.069843Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06655155","A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis",[12],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.741208Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT03844061","Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis",[12],"2026-08-26T02:19:29.922117Z","2026-05-05T02:43:27.633191Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT04380831","TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis",[45],"Early Phase 1","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.609078Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06655896","Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis",[12],"2026-08-26T02:19:02.550788Z","2026-05-05T02:43:27.576460Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT05878717","A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease",[58],"Phase 2\u002FPhase 3","2026-08-26T02:17:33.807405Z","2026-05-05T02:43:27.509044Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":66,"content_modified":67},"NCT07497087","A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis",[65],"Phase 3","2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.173709Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT07402226","Systemic Sclerosis DIet for GastrointESTinal Symptoms",[],"2026-08-26T02:16:56.877406Z","2026-05-05T02:43:27.042693Z",{"nct_id":75,"title":76,"phases":77,"status":13,"updated_at":78,"content_modified":79},"NCT05892614","Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)",[12],"2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.671761Z",{"nct_id":81,"title":82,"phases":83,"status":13,"updated_at":85,"content_modified":86},"NCT07085104","A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease",[84],"Phase 1","2026-08-26T02:16:26.411851Z","2026-07-30T01:46:14.415751Z",{"nct_id":88,"title":89,"phases":90,"status":13,"updated_at":91,"content_modified":92},"NCT06716606","A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)",[65],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:29.473028Z",{"nct_id":94,"title":95,"phases":96,"status":13,"updated_at":97,"content_modified":98},"NCT05869955","A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)",[84],"2026-08-03T03:31:16.569358Z","2026-05-05T02:43:29.019382Z",{"nct_id":100,"title":101,"phases":102,"status":13,"updated_at":103,"content_modified":104},"NCT07295847","A Study of AZD0120 in Autoimmune Diseases",[84],"2026-08-26T02:15:57.572488Z","2026-05-05T02:43:28.813958Z",{"nct_id":106,"title":107,"phases":108,"status":13,"updated_at":109,"content_modified":110},"NCT07047690","A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis",[12],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.619268Z",{"nct_id":112,"title":113,"phases":114,"status":13,"updated_at":115,"content_modified":116},"NCT03630211","Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis",[12],"2026-08-26T02:15:53.461103Z","2026-05-05T02:43:28.295890Z",{"nct_id":118,"title":119,"phases":120,"status":13,"updated_at":121,"content_modified":122},"NCT07115745","A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases",[84],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.679553Z",{"nct_id":124,"title":125,"phases":126,"status":13,"updated_at":127,"content_modified":128},"NCT06925542","A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease",[84],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:27.245332Z",{"nct_id":130,"title":131,"phases":132,"status":13,"updated_at":133,"content_modified":134},"NCT06672822","Intralesional Injection of STS in Treatment of Calcinosis",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.748851Z",{"nct_id":136,"title":137,"phases":138,"status":13,"updated_at":139,"content_modified":140},"NCT06434363","Phase I\u002FII Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders",[20],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:26.675534Z",{"nct_id":142,"title":143,"phases":144,"status":13,"updated_at":145,"content_modified":146},"NCT06991114","AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.",[12],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:26.665133Z",{"nct_id":148,"title":149,"phases":150,"status":13,"updated_at":151,"content_modified":152},"NCT05989763","Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis",[],"2026-08-26T02:18:29.369233Z","2026-05-05T02:35:31.758738Z",{"nct_id":154,"title":155,"phases":156,"status":13,"updated_at":157,"content_modified":158},"NCT06827977","A Study of Microbiome Transplantation for the Treatment of Constipation and\u002For Significant Bloating in Patients With Systemic Sclerosis",[12],"2026-08-26T02:16:48.735701Z","2026-05-05T02:35:31.681514Z",{"nct_id":160,"title":161,"phases":162,"status":13,"updated_at":163,"content_modified":164},"NCT06308978","A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease",[84],"2026-08-26T02:15:13.282904Z","2026-04-29T02:57:57.084867Z",{"nct_id":166,"title":167,"phases":168,"status":13,"updated_at":169,"content_modified":170},"NCT06733935","A Phase 1\u002F2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)",[20],"2026-08-26T02:18:18.766496Z","2026-06-16T05:54:07.925914Z",{"nct_id":172,"title":173,"phases":174,"status":13,"updated_at":175,"content_modified":176},"NCT03816345","Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO",[84],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:26.680299Z",{"nct_id":178,"title":179,"phases":180,"status":13,"updated_at":182,"content_modified":183},"NCT07112183","Open Label Treprostinil Raynaud's Study",[181],"Phase 4","2026-08-26T02:16:18.872924Z","2026-05-05T02:35:31.749897Z",{"nct_id":185,"title":186,"phases":187,"status":13,"updated_at":188,"content_modified":189},"NCT06675344","The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life",[],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:28.483758Z",{"nct_id":191,"title":192,"phases":193,"status":13,"updated_at":194,"content_modified":195},"NCT07228429","Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images",[],"2026-08-26T02:15:24.145250Z","2026-05-13T02:55:06.679677Z",{"nct_id":197,"title":198,"phases":199,"status":13,"updated_at":200,"content_modified":201},"NCT06708845","US Zamto-cel Autoimmune Diseases",[84],"2026-08-26T02:17:16.980188Z","2026-06-14T18:39:22.236937Z",{"nct_id":203,"title":204,"phases":205,"status":13,"updated_at":206,"content_modified":207},"NCT07403188","A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101",[],"2026-08-26T02:16:00.194860Z","2026-05-13T02:55:06.700539Z",{"nct_id":209,"title":210,"phases":211,"status":13,"updated_at":212,"content_modified":213},"NCT06587828","A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease",[],"2026-08-26T02:18:15.214990Z","2026-05-13T02:55:06.553094Z",{"nct_id":215,"title":216,"phases":217,"status":13,"updated_at":218,"content_modified":219},"NCT04402086","Rheumatology Patient Registry and Biorepository",[],"2026-08-26T02:18:39.640967Z","2026-05-13T02:55:06.248878Z",{"nct_id":221,"title":222,"phases":223,"status":13,"updated_at":224,"content_modified":225},"NCT03269630","New Orleans Pulmonary Hypertension Biobank",[],"2026-08-26T02:18:49.989941Z","2026-05-13T02:55:06.120229Z",{"nct_id":227,"title":228,"phases":229,"status":13,"updated_at":230,"content_modified":231},"NCT07090226","Diffuse Cutaneous Scleroderma (DSSc) SFDI Study",[],"2026-08-26T02:17:49.709549Z","2026-07-24T01:27:14.890471Z",{"nct_id":233,"title":234,"phases":235,"status":13,"updated_at":236,"content_modified":237},"NCT06646913","TENS in Scleroderma",[84],"2026-08-03T02:48:09.128334Z","2026-05-05T02:43:27.965091Z",{"nct_id":239,"title":240,"phases":241,"status":242,"updated_at":46,"content_modified":243},"NCT07335562","A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel \u002F Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis",[65],"NOT_YET_RECRUITING","2026-05-05T02:43:26.746670Z",{"nct_id":245,"title":246,"phases":247,"status":242,"updated_at":248,"content_modified":249},"NCT07697274","Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial",[45],"2026-08-26T02:17:20.511551Z","2026-07-19T19:36:05.174237Z",{"nct_id":251,"title":252,"phases":253,"status":242,"updated_at":254,"content_modified":255},"NCT07729995","BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease",[84],"2026-08-26T02:15:03.757872Z","2026-07-30T01:46:14.459181Z",{"nct_id":257,"title":258,"phases":259,"status":242,"updated_at":260,"content_modified":261},"NCT07691970","Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment",[65],"2026-08-26T02:18:24.494016Z","2026-07-19T19:36:05.153104Z",{"nct_id":263,"title":264,"phases":265,"status":266,"updated_at":267,"content_modified":268},"NCT07038447","A Study of KITE-363 in Participants With Refractory Autoimmune Diseases",[84],"ENROLLING_BY_INVITATION","2026-08-26T02:15:11.740957Z","2026-06-16T05:54:07.853790Z",{"nct_id":270,"title":271,"phases":272,"status":266,"updated_at":273,"content_modified":274},"NCT06375993","A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease",[84],"2026-08-26T02:16:24.970704Z","2026-06-16T05:54:07.753503Z",{"nct_id":276,"title":277,"phases":278,"status":279,"updated_at":280,"content_modified":281},"NCT06843239","Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:49:53.377789Z","2026-05-05T02:43:27.598303Z",[283,287],{"biomarker":284,"count":285,"slug":286},"Anti-ds DNA Antibody",3,"anti-ds-dna-antibody",{"biomarker":288,"count":285,"slug":289},"Antinuclear Antibody","antinuclear-antibody",[291,295,299,302,306,309,312,316,319,323,327,330,333,336,340,344,347,350,353,357,360,363,366,369],{"state":292,"count":293,"slug":294},"California",19,"california",{"state":296,"count":297,"slug":298},"Illinois",17,"illinois",{"state":300,"count":297,"slug":301},"Michigan","michigan",{"state":303,"count":304,"slug":305},"Florida",15,"florida",{"state":307,"count":304,"slug":308},"New York","new-york",{"state":310,"count":304,"slug":311},"Texas","texas",{"state":313,"count":314,"slug":315},"Massachusetts",13,"massachusetts",{"state":317,"count":314,"slug":318},"Pennsylvania","pennsylvania",{"state":320,"count":321,"slug":322},"North Carolina",10,"north-carolina",{"state":324,"count":325,"slug":326},"Minnesota",8,"minnesota",{"state":328,"count":325,"slug":329},"New Jersey","new-jersey",{"state":331,"count":325,"slug":332},"Ohio","ohio",{"state":334,"count":325,"slug":335},"South Carolina","south-carolina",{"state":337,"count":338,"slug":339},"Arizona",7,"arizona",{"state":341,"count":342,"slug":343},"Colorado",6,"colorado",{"state":345,"count":342,"slug":346},"Connecticut","connecticut",{"state":348,"count":342,"slug":349},"Louisiana","louisiana",{"state":351,"count":342,"slug":352},"Maryland","maryland",{"state":354,"count":355,"slug":356},"Iowa",5,"iowa",{"state":358,"count":355,"slug":359},"Kansas","kansas",{"state":361,"count":355,"slug":362},"Missouri","missouri",{"state":364,"count":355,"slug":365},"Tennessee","tennessee",{"state":367,"count":355,"slug":368},"Utah","utah",{"state":370,"count":371,"slug":372},"Alabama",4,"alabama"]